Correction: Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: Study protocol for a pilot randomised controlled trial (BJPsych Open (2015) 1:1 (67-73) DOI: 10.1192/bjpo.bp.115.001073);Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: Study protocol for a pilot randomised controlled trial

BJPsych Open

Volumn 1, Issue 1, 2015, Pages 67-73

  Mayfield, Karla ^a   Siskind, Dan ^b   Winckel, Karl ^a   Hollingworth, Samantha ^a   Kisely, Steve ^b   Russell, Anthony W ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84977745946     PISSN: None     EISSN: 20564724     Source Type: Journal    
DOI: 10.1192/bjpo.bp.116.003103     Document Type: Erratum

References (39)

1. Mcilwain ME, Harrison J, Wheeler AJ, Russell BR. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat 2011; 7: 135-49.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
3. Wetterling T. Bodyweight gain with atypical antipsychotic: a comparative review. Drug Safety 2001; 24: 59-73.
4. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157: 975-81.
5. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19: 1-93.
6. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565-7.
7. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
8. Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM. Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol 2015; 71: 389-401.
9. Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009; 113: 19-26.
10. Chen CH, Huang MC, Kao CF, Lin SK, Kuo PH, Chiu CC, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74: e424-30.
11. Smith GC, Vickers MH, Cognard E, Shepherd PR. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 2009; 115: 30-40.
12. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-39.
13. Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 2008; 51: 2309-17.
14. Lykkegaard K, Larsen PJ, Vrang N, Bock C, Bock T, Knudsen LB. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr Res 2008; 103: 94-103.
15. Dixit TS, Sharma AN, Lucot JB, Elased KM. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol Behav 2013; 114-115: 38-41.
16. Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. Obesity 2015; 23: 1119-29.
17. Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010; 10: 20.
18. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005; 146: 2069-76.
19. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
20. Zhang F, Tong Y, Su N, Li Y, Tang L, Huang L, et al. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: a systematic review and meta-analysis of randomized controlled trials. J Diabetes 2015; 7: 329-39.
21. Ishøy PL, Knop FK, Vilsboll T, Glenthoj BY, Ebdrup BH. Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. Am J Psychiatry 2013; 170: 681-2.
22. Ishøy PL, Knop FK, Broberg BV, Baandrup L, Fagerlund B, Jørgensen NR, et al. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist-protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. BMJ Open 2014; 4: e004158.
23. Larsen JR, Vedtofte L, Holst JJ, Oturai P, Kjaer A, Corell CU, et al. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial. BMJ Open 2014; 4: e004227.
24. Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet 2002; 359: 515-9.
25. Bydureon (exenatide). Australian approved product information. AstraZeneca, 2015.
26. Paul SK, Maggs D, Klein K, Best JH. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly. J Diabetes 2015; 7: 60.
27. The Royal Australian College of General Practitioners, Diabetes Australia. General Practice Management of Type 2 Diabetes - 2014-15. The Royal Australian College of General Practitioners, Diabetes Australia, 2014.
28. Turner RC, Holman RR, Stratton IM, Cull CA. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
29. Institute of Medicine. Weighing the Options: Criteria for Evaluating Weight Management Programs. National Academy Press, 1995.
30. Australian Commission on Safety and Quality in Health Care. National Adult Clozapine Titration Chart User Guide. Australian Commission on Safety and Quality in Health Care, 2012.
31. Lachar D, Bailley SE, Rhoades HM, Espadas A, Aponte M, Cowan KA, et al. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychol Assess 2001; 13: 384-95.
32. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12.
33. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceut Statist 2005; 4: 287-91.
34. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004; 10: 307-12.
35. Harris KB, McCarty DJ. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab 2015; 6: 3-18.
36. Johnston SS, Nguyen H, Felber E, Cappell K, Nelson JK, Chu BC, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther 2014; 31: 1119-33.
37. Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med 2009; 26: 722-8.
38. Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50: 65-74.
39. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-50.